ArticleGastro hep advances2024

Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies.

Laurent Peyrin-Biroulet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.